ELIQUIS $10 Co-pay Card*

Eligible patients may be able to take advantage of this savings offer. Contact a representative at 1‑855‑ELIQUIS for more information.

Eligible patients with commercial insurance who comply with the Terms of Use can pay no more than $10 per month for a 30-day supply for up to 24 months with the ELIQUIS Co-pay Card.*

  • Subject to a maximum annual benefit of $3,800
No meal requirements or food restrictions

To get ELIQUIS $10 Co-pay Cards for your patients, please contact a representative at 1-855-ELIQUIS.

$10 CO-PAY CARD ELIGIBILITY REQUIREMENTS:

  • You may be eligible for the Co-pay Card for ELIQUIS® (apixaban) if:
  1. You are insured by commercial insurance and your prescription insurance coverage does not cover the full cost of your prescription, that is, you have a co-pay obligation for ELIQUIS;
  2. You do not have prescription insurance coverage through a state or federal healthcare program, including but not limited to Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), or Department of Defense (DOD) programs; patients who move from commercial plans to state or federal healthcare programs will no longer be eligible;
  3. You are 18 years of age or older; and
  4. You are a resident of the United States or Puerto Rico.

One-time, free 30-day trial for eligible patients who are commercially and government-insured (including Medicare and Medicaid) as well as those who are cash-paying

  • Offer limited to one per patient upon redemption of their first valid 30-day prescription at a pharmacy
No meal requirements or food restrictions

To get ELIQUIS free trial cards for your patients, please contact a representative at 1-855-ELIQUIS.

30-DAY FREE TRIAL OFFER ELIGIBILITY REQUIREMENTS:

  • You may be eligible for the Free 30-Day Trial Offer for ELIQUIS® (apixaban) if:
  1. You have not previously filled a prescription for ELIQUIS;
  2. You have a valid 30-day prescription for ELIQUIS;
  3. You are being treated with ELIQUIS for an FDA-approved indication that an HCP has planned for more than 35 days of treatment;
  4. You are 18 years of age, or older; and
  5. You are a resident of the United States or Puerto Rico.

Available at ELIQUIS.com, ELIQUIS 360 Support provides helpful, ongoing support, including co-pay and free trial offers, prescription coverage assistance, and more.


The ELIQUIS Starter Pack

Designed to support DVT/PE treatment initiation, the ELIQUIS Starter Pack offers your patients their first 30-day supply of ELIQUIS treatment complete with daily dosing instructions.

The ELIQUIS Starter Pack includes:

  • 2 separate wallets per box
    - Wallet 1 contains ELIQUIS treatment for days 1–14 along with directions on how to step down dosing after week 1
    - Wallet 2 contains ELIQUIS treatment for days 15–30
  • Refill reminder: prompts DVT/PE patients to refill their ELIQUIS prescription

No cost to eligible patients for the first 30 days of their prescription when using the ELIQUIS Free Trial Offer. Eligibility Requirements and Terms of Use apply.

Patient Educational Resources

Use these patient-friendly, informative resources to help you explain to your patients their medical condition, why they are being prescribed ELIQUIS, and how ELIQUIS works.

  • 1 Patient Education Videos

These animated videos can help your patients understand nonvalvular atrial fibrillation (NVAF) and its associated risk of stroke; deep vein thrombosis (DVT), pulmonary embolism (PE); and the need for anticoagulants like ELIQUIS for appropriate patients

  • 2 Helpful Downloads
Signs of a Stroke (PDF)

A simple reference for patients and caregivers to keep handy

Image for the Signs of a Stroke handout for patients with nonvalvular atrial fibrillation
ELIQUIS DVT/PE Starter Guide (PDF)

Patient-friendly information about DVT/PE and treatment with ELIQUIS

Image of the starter guide for patients with DVT/PE who are starting this anticoagulant
IMPORTANT SAFETY INFORMATION

WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA

(A) Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.

(B) Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:

  • use of indwelling epidural catheters
  • concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants
  • a history of traumatic or repeated epidural or spinal punctures
  • a history of spinal deformity or spinal surgery
  • optimal timing between the administration of ELIQUIS and neuraxial procedures is not known

Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.

Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated.

CONTRAINDICATIONS

  • Active pathological bleeding
  • Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions)

WARNINGS AND PRECAUTIONS

  • Increased Risk of Thrombotic Events after Premature Discontinuation: Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients. If ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.
  • Bleeding Risk: ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding.

    • Concomitant use of drugs affecting hemostasis increases the risk of bleeding, including aspirin and other antiplatelet agents, other anticoagulants, heparin, thrombolytic agents, SSRIs, SNRIs, and NSAIDs.
    • Advise patients of signs and symptoms of blood loss and to report them immediately or go to an emergency room. Discontinue ELIQUIS in patients with active pathological hemorrhage.
    • There is no established way to reverse the anticoagulant effect of apixaban, which can be expected to persist for at least 24 hours after the last dose (i.e., about two half-lives). A specific antidote for ELIQUIS is not available.
  • Spinal/Epidural Anesthesia or Puncture: Patients treated with ELIQUIS undergoing spinal/epidural anesthesia or puncture may develop an epidural or spinal hematoma which can result in long-term or permanent paralysis.

    The risk of these events may be increased by the postoperative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis. Indwelling epidural or intrathecal catheters should not be removed earlier than 24 hours after the last administration of ELIQUIS. The next dose of ELIQUIS should not be administered earlier than 5 hours after the removal of the catheter. The risk may also be increased by traumatic or repeated epidural or spinal puncture. If traumatic puncture occurs, delay the administration of ELIQUIS for 48 hours.

    Monitor patients frequently and if neurological compromise is noted, urgent diagnosis and treatment is necessary. Physicians should consider the potential benefit versus the risk of neuraxial intervention in ELIQUIS patients.

  • Prosthetic Heart Valves: The safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves and is not recommended in these patients.
  • Acute PE in Hemodynamically Unstable Patients or Patients who Require Thrombolysis or Pulmonary Embolectomy: Initiation of ELIQUIS is not recommended as an alternative to unfractionated heparin for the initial treatment of patients with PE who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy.

ADVERSE REACTIONS

  • The most common and most serious adverse reactions reported with ELIQUIS were related to bleeding.

TEMPORARY INTERRUPTION FOR SURGERY AND OTHER INTERVENTIONS

  • ELIQUIS should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding. ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be noncritical in location and easily controlled. Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required. ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established.

DRUG INTERACTIONS

  • Combined P-gp and Strong CYP3A4 Inhibitors: Inhibitors of P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4) increase exposure to apixaban and increase the risk of bleeding. For patients receiving ELIQUIS doses of 5 mg or 10 mg twice daily, reduce the dose of ELIQUIS by 50% when ELIQUIS is coadministered with drugs that are combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, or ritonavir). In patients already taking 2.5 mg twice daily, avoid coadministration of ELIQUIS with combined P-gp and strong CYP3A4 inhibitors. Clarithromycin Although clarithromycin is a combined P-gp and strong CYP3A4 inhibitor, pharmacokinetic data suggest that no dose adjustment is necessary with concomitant administration with ELIQUIS.
  • Combined P-gp and Strong CYP3A4 Inducers: Avoid concomitant use of ELIQUIS with combined P-gp and strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) because such drugs will decrease exposure to apixaban.
  • Anticoagulants and Antiplatelet Agents: Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. APPRAISE-2, a placebo-controlled clinical trial of apixaban in high-risk post-acute coronary syndrome patients treated with aspirin or the combination of aspirin and clopidogrel, was terminated early due to a higher rate of bleeding with apixaban compared to placebo.

PREGNANCY CATEGORY B

  • There are no adequate and well-controlled studies of ELIQUIS in pregnant women. Treatment is likely to increase the risk of hemorrhage during pregnancy and delivery. ELIQUIS should be used during pregnancy only if the potential benefit outweighs the potential risk to the mother and fetus.
INDICATIONS

ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.

ELIQUIS is indicated for the treatment of DVT and PE, and to reduce the risk of recurrent DVT and PE following initial therapy.

Please see U.S. FULL PRESCRIBING INFORMATION including Boxed WARNINGS, and MEDICATION GUIDE.

ELIQUIS is available in 2.5 mg and 5 mg tablets.

SELECTED IMPORTANT SAFETY INFORMATION

WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS,(B) SPINAL/EPIDURAL HEMATOMA

(A) Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.

See Full Boxed WARNINGS

ELIQUIS® and the ELIQUIS logo are trademarks of Bristol-Myers Squibb Company. All other trademarks are the property of their respective owners.
© Bristol-Myers Squibb Company. 432US1801092-01-01  04/18